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Combined antitumor effects of bee venom and cisplatin on 
human cervical and laryngeal carcinoma cells and their
drug resistant sublinesGoran Gajski, Tamara Čimbora-Zovko, Sanjica Rak, Marko Rožman, Maja Osmak and Vera Garaj-VrhovacABSTRACT: In the present study, we investigated the possible combined anticancer ability of bee venom (BV) and cisplatin 
towards two pairs of tumour cell lines: parental cervical carcinoma HeLa cells and their cisplatin-resistant HeLa CK subline, as 
well as laryngeal carcinoma HEp-2 cells and their cisplatin-resistant CK2 subline. Additionally, we identiﬁed several peptides 
of BV in the BV sample used in the course of the study and determined the exact concentration of MEL. BV applied alone in 
concentrations of 30 to 60 μg m l –1 displayed dose-dependent cytotoxicity against all cell lines tested. Cisplatin-resistant 
cervical carcinoma cells were more sensitive to BV than their parental cell lines (IC50 values were 52.50 μg m l –1 for HeLa vs. 
47.64 μg m l –1 for HeLa CK cells), whereas opposite results were obtained for cisplatin-resistant laryngeal carcinoma cells 
(IC50 values were 51.98 μg m l –1 for HEp-2 vs. > 60.00 μg m l –1 for CK2 cells). Treatment with BV alone induced a necrotic 
type of cell death, as shown by characteristic morphological features, fast staining with ethidium-bromide and a lack of 
cleavage of apoptotic marker poly (ADP-ribose) polymerase (PARP) on Western blot. Combined treatment of BV and cisplatin 
induced an additive and/or weak synergistic effect towards tested cell lines, suggesting that BV could enhance the killing 
effect of selected cells when combined with cisplatin. Therefore, a greater anticancer effect could be triggered if BV was used 
in the course of chemotherapy. Our results suggest that combined treatment with BV could be useful from the point of 
minimizing the cisplatin concentration during chemotherapy, consequently reducing and/or postponing the development of 
cisplatin resistance. 
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MEL is a small protein containing 26 amino acids and it is theIntroduction
Regardless of major scientiﬁc and technological advancements
in combinatorial chemistry, drugs derived from natural products
still make an enormous contribution to drug discovery today
(Cragg and Newman, 2000; Gordaliza, 2007; da Rocha et al.,
2001). A large number of studies in the past few years have
reported on the anticancer ability of a wide spectra of natural
products derived from plants and animals (Mehta and Pezzuto,
2002; Nobili et al., 2009), and the majority of those studies are
especially interested in the effects of venoms from snakes,
spiders, scorpions and in particular from honeybees (Heinen and
da Veiga, 2011; Oršolić, 2012; Son et al., 2007) towards different
types of tumour cell lines. Venom from Apis mellifera has been
used for centuries in traditional medicine as a source of drugs to
cure different ailments (Cherniack, 2010; Gajski and Garaj-Vrhovac,
2011; Garaj-Vrhovac and Gajski, 2009; Son et al., 2007).
Several beneﬁcial roles of BV are also known today, such as
radioprotective (Gajski and Garaj-Vrhovac, 2009), antimutagenic
(Varanda et al., 1999), antinociceptive (Baek et al., 2006) and in
recent times anticancer effects (Oršolić, 2012; Son et al., 2007).
Recent reports indicate several mechanisms of BV cytotoxicity
on different types of cancer cells such as cell cycle alterations,
effects on proliferation and/or growth inhibition, as well as induc-
tion of apoptosis or necrosis (Gajski et al., 2011; Hu et al., 2006;Ip et al., 2008a, b, 2012; Jang et al., 2003; Jo et al., 2012; Lee et al., 
2007; Liu et al., 2002; Moon et al., 2006; Oršolić, 2009; Park et al., 
2011). Therefore, BV has generated a great deal of interest as a 
possible therapeutic modality.
Venom itself is a very complex mixture of a variety of different 
active peptides: melittin (MEL), apamin, adolapin and mast cell 
degranulating (MCD) peptide (Habermann, 1972; Hider, 1988). 
In addition, it also contains enzymes, biologically active amines 
and non-peptide components including lipids, carbohydrates and 
free amino acids all with many cellular activities (Lariviere and 
Melzack, 1996). Two major components of BV are MEL and 
principal toxin in the BV, constituting around 50% of the whole BV
according to the literature (Oršolić, 2012; Son et al., 2007). MEL has
a broad range of actions towards different types of cells through its
interactions with the plasma membrane and the enzyme system,
and its lytic activity is probably caused by its ability to insert
into phospholipids layers (Dempsey, 1990; Raghuraman and
Chattopadhyay, 2007). PLA2, which makes around 10% of the
whole BV, is a member of the group of enzymes that catalyze the
hydrolysis of the sn-2 fatty acyl-ester bond of membrane glycero-
3-phospholipids resulting in diverse biological effects (Kwon
et al., 2002; Six and Dennis, 2000; Valentin and Lambeau, 2000).
Hydrolysis of these compounds generates lysophospholipids. In-
terestingly, lysolipids have therefore been proposed for anticancer
therapies because of their antiproliferative effects and cytotoxicity
(Ashagbley et al., 1996; Putz et al., 2006; Samadder et al., 2004).
The major obstacle for successful treatment of tumour patients
with the standard chemotherapy is the development of drug resis-
tance during the course of chemotherapy. Cisplatin is today one of
themost widely used anticancer drugs for the treatment of a num-
ber of solid tumours (Boulikas and Vougiouka, 2003). It is generally
accepted that cisplatin is a DNA damaging agent, because its
cytotoxic effect is based upon the formation of platinum–DNA
adducts. As the consequence of DNA platination, the cell cycle is
arrested in order to allow the cell to repair the damage. If repair
fails, apoptosis is induced by activation of various pathways (Fink
& Howell, 2000; Fuertes et al., 2003). However, recently it has been
found that cisplatin can also induce non-DNA damage owing to
formation of reactive oxygen species (ROS) (Brozović et al., 2010).
The therapeutic outcome of cisplatin-based chemotherapy can
be impaired by intrinsic or acquired resistance. Cisplatin resistance
is the consequence of multifactor events. Several molecular mech-
anisms of resistance may occur in the same cell population. They
include decreased accumulation and increased detoxiﬁcation of
cisplatin, more efﬁcient removal of platinum–DNA adducts, an
enhanced capacity to replicate past adducts, inhibition of apopto-
sis and a recently recognized mechanism, cell adhesion-mediated
cisplatin resistance (Brozović et al., 2008, 2010; Köberle et al., 2010;
Stewart, 2007; Zisowsky et al., 2007).
The aim of the present study was to investigate the possible com-
bined anticancer ability of BV and cisplatin towards tumour cells
in vitro. As the content of BV can be inﬂuenced bymany factors, ﬁrst
we identiﬁed several peptides of BV in the BV sample used in the
course of the study and determined the exact concentration of
MEL. Next, we examined the cytotoxic effect of BV alone on parental
cervical carcinoma HeLa cells and laryngeal carcinoma HEp-2 cells,
as well as their cisplatin-resistant HeLa CK and CK2 sublines, respec-
tively. Because sublethal concentrations of BV can stimulate cell
growth, we used higher BV concentrations, all a bit lower than those
which induce the killing of a large part of the treated cell population.
According to our previous data the doses used were between 30
and 60 μg ml–1 of BV (Gajski et al., 2011). Additionally, we exam-
ined morphological changes and the type of cell death that was
induced by BV. Finally, we investigated the combined treatment
of cisplatin and BV on parental and cisplatin-resistant cells lines.
Materials and Methods
Chemicals and Cell Media
BV,MEL, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide
(MTT), antibiotics (penicillin and streptomycin) and cisplatin (cDDP)
were purchased from Sigma (St Louis, MO, USA); acridine-orange(AO), Coomassie Brilliant Blue G-250 and ethidium-bromide (EtBr)
were from Serva (Heidelberg, Germany); bovine serum albumin
(BSA) and Dulbecco’s modiﬁed Eagle’s medium (DMEM) were from
Gibco (Gaithersburg, MD, USA). All other chemicals not speciﬁcally
cited here were purchased from Kemika (Zagreb, Croatia).Analysis of BV by Mass Spectrometry
Mass spectrometry (MS) and tandem MS experiments were
performed on a Bruker amaZon ETD ion trap system (Bruker
Daltonik GmbH, Bremen, Germany) which incorporates a negative
chemical ionization source capable of providing reagent anions for
both electron transfer dissociation (ETD) and proton transfer reac-
tion (PTR). Solutions of BV and MEL were prepared by dissolving
dried samples in ethanol/water (50:50, 0.1% formic acid). All sam-
ples were introduced into the electrospray ionization (ESI) source
by direct infusion at a ﬂow rate of 65 μl h–1. The temperature
and ﬂow rate of the drying gas were set at 210 °C and 5 l min–1,
respectively. ETD, PTR and collision induce dissociation (CID)
conditions were optimized in order to maximize the dissociation
and the appearance of the product ion spectra. All spectra were
acquired in a positive mode using a scan range from 200 to
3000 m/z. DataAnalysis software 4.0 (Bruker Daltonik GmbH) was
used for analysis (charge deconvolution and data reduction) and
extraction of the MS and tandem MS data. Peptide sequence
assignment was done using BioTools 3.2 (Bruker Daltonik GmbH).
The concentration of MEL in the BV sample was determined
by direct infusion ESI-MS, without chromatographic separation.
A calibration curve was obtained by plotting the peak height
of the MEL-extracted ion chromatogram (all available charge
states) as a function of the concentration.Cell Cultures
Human cervical carcinoma HeLa cells and their drug-resistant
subline HeLa CK as well as human laryngeal carcinoma HEp-2
cells and their drug-resistant CK2 subline were used in the pres-
ent study. Cisplatin-resistant HeLa CK cells were derived from
the human cervical carcinoma HeLa cell line (Osmak and Eljuga,
1993), whereas cisplatin-resistant CK2 cells were derived from
HEp-2 cells as described previously (Osmak, 1992; Osmak et al.,
1993). All cell lines were maintained as a monolayer culture in
DMEM (Gibco) supplemented with 10% BSA (Gibco) and antibi-
otics (penicillin and streptomycin) in a humiﬁed atmosphere at
37 °C with 5% CO2 and were sub-cultured every 3–4 days.Cell Treatment with BV
Cells were seeded and after overnight incubation, they were treated
with BV. Just before the beginning of the treatment, BVwas dissolved
in sterile redistilled water at 25 °C as 1 mg ml–1 stock solution and
thendissolved in growthmedium to abroad rangeof concentrations.
At a certain time point after the treatment, cells were collected for fur-
ther experiments. Each experiment was repeated two or three times.Cytotoxicity Assay
Cytotoxicity of the whole BV towards cervical HeLa and laryngeal
Hep-2 carcinoma parental cells and their drug-resistant HeLa CK
and CK2 sublines was determined by the modiﬁed colorimetric
MTT assay (Mickisch et al., 1990). Additionally, we used the same
test to evaluate the cell response to cisplatin treatment as well as
to combined treatment with BV and cisplatin. MTT stains cells that
have active mitochondria, i.e. live viable cells. Brieﬂy, 2.5 × 103 cells
were seeded into 96-well microtiter tissue culture plates. On the
following day, the medium was aspirated and replaced with fresh
growth medium in which appropriate concentrations of whole BV
diluted in medium was added. Each concentration was tested in
triplicate. The cells were continuously treated with BV for 72 h at
37 °C. For the combined treatmentwith BV and cisplatin, cells were
pretreated with concentrations of BV for 1 h and then different
concentrations of cisplatin were added to the cultures. After 72 h
the medium was aspirated and 20 μg of MTT dye per 0.04 ml
medium was added to each well. After 4 h of incubation at 37 °C,
formazan crystals were dissolved in dimethyl sulfoxide (DMSO;
0.17 ml per well), the plates were mechanically agitated for 5 min
and the absorbance at 545 nm was determined on a microtiter
plate reader (Awareness Technology Inc., Palm City, FL, USA).Morphological Changes and the Type of Cell Death
Next, 2.5 × 103 cells per well of cervical carcinoma HeLa cells or
their drug-resistant subline HeLa CK cells were plated in tissue
culture plates. Cells were then incubated with the whole BV at
different concentrations for 1 h. As a positive control cells were
treated for 24 h with 20 μM cisplatin which is known to induce
apoptotic cell death (Eastman, 1990). The type of cell death
was determined by staining cells with DNA-intercalators AO
and EtBr, which give green ﬂuorescence of the nuclei in live cells
and red ﬂuorescence of the nuclei in dead cells, respectively. In
brief, adherent and ﬂoating cells were collected by centrifuga-
tion and resuspended in a small volume of culture medium, after
which in 10 μl of cell suspension, 2 μl of AO [15 μg ml–1 in phos-
phate-buffered saline (PBS)] and 2 μl of EtBr (50 μg ml–1 in PBS)
were added. Samples were viewed under the epiﬂuorescence
microscope Axiovert 35 (Opton, Germany). Fluorescence was
detected through the BP 450-490, FT 510, LP 520 ﬁlter. Images
were taken with the camera Pixera Pro150ES (San Jose, CA, USA).Western Blot Analysis
Next, 4 × 105 cells were seeded and on the next day treated with
the whole BV in different concentrations. As a positive control,
cells were treated for 24 h with 20 μM cisplatin which is known
to induce apoptotic cell death (Eastman, 1990). Total cellular
extracts were obtained by lysing the cells in lysis buffer (25 mM
HEPES, pH 7.5, 150 mM NaCl, 1% Triton X-100, 10 mM MgCl2,
1 mM EDTA, 2% glycerol, 1 mM PMSF) on ice. The protein concen-
tration was determined by Bradford (1976) and equal amounts of
protein were separated by SDS–PAGE (12.5%) and blotted onto
nitrocellulosemembrane (Schleicher & Schüll, Dassel, Germany). Af-
ter overnight incubation at 4 °C in blocking buffer [5% milk (w/v) in
TBS buffer with 0.1% Tween20 (v/v)], themembranes were probed
with monoclonal antibody against poly(ADP-ribose) polymerase
(PARP; Pharmingen, San Diego, CA, USA). Primary antibodies were
detected with corresponding horseradish-peroxidase conjugated
secondary antibodies (GE Healthcare, Piscataway, NJ, USA),
followed byWestern Blot Chemiluminescence Reagent Plus detec-
tion according to the protocol provided by the manufacturer
(PerkinElmer Life Science, Boston, MA, USA). As an internal protein
loading control, ERK2 protein expression was determined by re-
probing the membranes with ERK2 speciﬁc rabbit polyclonal
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA).Statistical Analysis
The isobologram analysis method was used to determine the
extent of synergism on combining two agents for their possible
therapeutic effect. The synergy index (q) was calculated according
to the formula q = E(A + B)/(EA + EB  EA × EB) (Jin, 1980). This
method was used to elucidate the possible additive and/or syner-
gistic effect of BV and cisplatin. E(A + B) represent the inhibition
rate of the combination group, and EA and EB represent the indi-
vidual group. If the value of q ranges from 0.85 to 1.15, the role of
combination is just the simple addictive effect. While from 1.15 to
2.0, the role of combination will be a synergistic effect. Greater
than 2.0, it represents that there is a signiﬁcant synergistic effect
between the two agents. Statistical differences between the mean
values were calculated using Student’s t-test. Differences were
considered signiﬁcant when P < 0.05.Results
Analysis of BV Content
MS and tandem MS experiments were performed in order to
examine the content of BV and to determine the exact concen-
tration of MEL in BV that was used in the present study. Peptides
MEL, apamin, MCD peptide and tertiapin were identiﬁed by tan-
dem MS as components of BV. Charge deconvoluted low-energy
CID/ETD spectra are shown on Fig. 1. Identiﬁed peptides are in
agreement with previous ﬁndings regarding peptide compo-
nents of BV (Oršolić, 2012; Son et al., 2007). Additionally, the
concentration of MEL in BV was determined (Fig. 2). MEL mass
fraction in the BV sample was estimated at 0.19.Cytotoxicity of BV in vitro
A cytotoxic effect of whole BVwas evaluated on human cervical car-
cinoma HeLa cells and human laryngeal carcinoma HEp-2 cells and
their drug-resistant HeLa CK and CK2 sublines, respectively. The re-
sults of theMTT assay are presented in Fig. 3. BVwas cytotoxic for all
examined cell lines, and the toxicity was dose dependent. The cyto-
toxicity was also cell type dependent. Although parental HeLa and
HEp-2 cells exhibited almost the same sensitivity with IC50 values of
52.50 and 51.98 μg ml–1, respectively, we observed a different pat-
tern in the sensitivity of their drug-resistant sublines. HeLa CK cells
were more sensitive towards BV than the parental cells with the
IC50 value of 47.64 μg ml
–1, compared with CK2 cells that displayed
the highest resistance towards BV with a IC50 above 60.00 μg ml
–1.BV-InducedMorphological Changes and the Type of Cell Death
Light and ﬂuorescent microscopy was used for the determina-
tion of morphological changes induced in the pair of cervical
carcinoma cells: parental HeLa cells and their cisplatin-resistant
HeLa CK subline. On both cell lines we saw similar morphological
alterations that were induced rapidly after the addition of whole
BV: rounded and granulated cells, shrinkage, and separation
from neighbouring cells and eventual detachment from the
culture plates (Fig. 4). Very few such features were observed in
the control cells. One hour after the treatment we also determined
the type of cell death using ﬂuorescent microscopy. As shown in
Fig. 4, BV induced a necrotic type of cell death in both HeLa and
HeLa CK cells as opposed to treatment with cisplatin where
apoptosis was observed. Detection of cells dying by a necrotic
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Figure 2. Melittin (MEL) calibration curve obtained by direct infusion electrospray ionization-mass spectrometry (ESI-MS) assay.
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Figure 1. Charge deconvoluted low-energy collision induce dissociation/electron transfer dissociation (CID/ETD) spectrum of (A) melittin
(GIGAVLKVLTTGLPALISWIKRKRQQ), (B) apamin (CNCKAPETALCARRCQQH – amidated C-terminus, crosslink SS 1-11 and SS 3-15), (C) mast cell degranulating
peptide (IKCNCKRHVIKPHICRKICGKN – amidated C-terminus, crosslink SS 3-15 and SS 5-19) and (D) tertiapin (ALCNCNRIIIPHMCWKKCGKK – amidated
C-terminus, crosslink SS 3-14 and SS 5-18).
AB
Figure 4. Microphotographs of human cervical carcinoma HeLa cells and their drug-resistant HeLa CK subline after bee venom (BV) treatment (μg ml–1).
Cells were incubated for 1 h with indicated concentrations of BV and viewed and photographed under the light microscope to determined morphological
changes induced by the treatment with the whole BV. Pictures were taken at magniﬁcation 400× (A). For determination of apoptotic and/or necrotic nuclear
morphology cells were also incubated for 1 h with indicated concentrations of BV, stained with DNA-intercalators acridine-orange (AO) and ethidium-
bromide (EtBr), and viewed and photographed under the epiﬂuorescent microscope. Pictures were taken at magniﬁcation 1000× (B). As a positive
control cells were treated for 24 h with cisplatin (cDDP, 20 μM) which is known to induce apoptotic cell death.
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Figure 3. Cytotoxic effect of bee venom (BV) on human cervical carcinoma HeLa cells (A) and human laryngeal carcinoma HEp-2 cells (B) and their
drug-resistant HeLa CK and CK2 sublines, respectively. Cells were seeded in 96-well tissue culture plates and 24 h later BV was added. Cells were
incubated for 72 h with indicated concentrations of BV and percentage of cell viability was calculated in relation to the untreated control. The viability
was determined with the modiﬁed colorimetric MTT assay. *Statistically signiﬁcant compared with the corresponding control (P < 0.05).type of cell death employs the fact that, in contrast to apoptosis,
the cell membrane becomes permeable very early, but the nucleus
disintegrates late. So, pyknotic and fragmented nuclei are charac-
teristic for apoptosis, but round and intact nuclei indicate a
necrotic type of cell death. It is important to note that cells in the
late stages of apoptosis are also membrane permeable owing to
secondary necrosis.
Induction of PARP Cleavage by BV
Using morphological alteration and staining with ﬂuorescent
dyes, we show in this study that BV induces necrosis in bothHeLa and HeLa CK cells. However, to conﬁrm this observation,
we additionally explored whether BV can induce apoptosis. For
this purpose we used HeLa cells and examined whether treat-
ment with BV induces cleavage of PARP, which is a regulatory
molecule whose cleavage is known to indicate apoptotic cell
death (Kaufmann et al., 1993). As expected, Western blot analysis
did not show any cleavage of PARP as shown in Fig. 5.
Effect of Combined Treatment with BV and Cisplatin
To test the impact of the combined treatment of BV and cisplatin,
human cervical carcinoma HeLa cells and human laryngeal
carcinoma HEp-2 cells, as well as their cisplatin-resistant HeLa CK
and CK2 sublines, were pre-treated with BV in different concentra-
tions for 1 h, after which cisplatin was added. Cytotoxicity of such a
combined treatment against human cervical carcinoma HeLa cells
and their cisplatin-resistant HeLa CK subline is shown in Fig. 6,
whereas cytotoxicity on human laryngeal carcinoma HEp-2 cells
and their cisplatin-resistant CK2 subline was shown in Fig. 7. When
combined treatment with cisplatin and BV was given to HeLa cells,A
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Figure 6. Sensitivity of human cervical carcinoma HeLa cells (A) and their
venom (BV) and cisplatin (cDDP). Cells were seeded in 96-well tissue culture
indicated concentrations of BV (μg ml–1) after treatment with indicated con
in relation to untreated control. The viability was determined with the modiﬁ
sent cell viability obtained with BV treatment (from 0 to 50 μg ml–1), light
obtained with indicated cDDP doses, whereas light-gray and dark-gray colu
combined treatment with BV and cisplatin. *Statistically signiﬁcant compare
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Figure 7. Sensitivity of human laryngeal carcinoma HEp-2 cells (A) and th
venom (BV) and cisplatin (cDDP). Cells were seeded in 96-well tissue culture
indicated concentrations of BV (μg ml–1) after treatment with indicated con
in relation to untreated control. The viability was determined with the modiﬁ
sent cell viability obtained with BV treatment (from 0 to 50 μg ml–1), light-gray
with indicated cDDP doses, while light-gray and dark-gray columns (under 30
ment with BV and cisplatin. *Statistically signiﬁcant compared with the corre
Figure 5. Determination of cell death after bee venom (BV) treatment.
Human cervical carcinoma HeLa cells were incubated for 1 h with indi-
cated concentrations of BV. As a positive control cells were also treated
with cisplatin (cDDP, 20 μM) for 24 h which is known to induce apoptotic
cell death. The induction of apoptosis was determined by the cleavage
of characteristic apoptotic protein poly (ADP-ribose) polymerase (PARP)
by Western blot analysis. As an internal protein loading control, ERK2
protein expression was determined by re-probing the membranes with
ERK2-speciﬁc antibody. A representative of three independent experi-
ments is shown.cell sensitization was observed for a higher dose of cisplatin, and
the highest dose of BV and a higher dose of cisplatin. In contrast,
all three given doses of BV sensitized HeLa CK cells to both doses
of cisplatin (Fig. 6). The combination of BV and cisplatin was again
less cytotoxic to parental laryngeal carcinoma cells, while all three
selected doses of BV increased the cell sensitivity of CK2 cells to
both doses of cisplatin (Fig. 7). Thus, according to statistical analy-
sis, both cisplatin-resistant sublines, HeLa CK and CK2 cells were
more sensitive to cisplatin when pre-treated with BV compared
with parental cells. The isobologram analysis method showed that
the effect of BV and cisplatin, given in combination, on HeLa and
HeLa CK cells was synergistic (q ranges from 1.15 to 2.0) for all
the BV and cisplatin concentrations, although a signiﬁcant syner-
gistic effect was not observed. In contrast, the synergistic effect
on HEp-2 cells was observed only for the highest BV concentration
and for both cisplatin doses, whereas on CK2 cells only 40 μg ml–1
BV and both cisplatin doses showed a synergistic effect. It has to
be pointed out that the synergistic effect was again non-signiﬁcant
since q was lower than 2.0. All the other BV and cisplatin concen-
trations on HEp-2 and CK2 cells only gave an additive effect.
Discussion
Today there is increasing interest in anticancer treatment strategies
involving natural products such as BV and strategies that combine
standard chemotherapy with novel agents that could target cancerB
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drug-resistant HeLa CK cell subline (B) towards joint treatment with bee
plates and 24 h later BV was added. Cells were pre-treated for 1 h with
centrations of cDDP (μM) and percentage of cell viability was calculated
ed colorimetric MTT assay after 72 h of treatment. White columns repre-
-gray and dark-gray columns (under 0 μg ml–1 BV ) represents viability
mns (under 30, 40 or 50 μg ml–1 BV) represent cell viability obtained by
d with the corresponding cDDP treatment (P < 0.05).
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eir drug-resistant CK2 cell subline (B) towards joint treatment with bee
plates and 24 h later BV was added. Cells were pre-treated for 1 h with
centrations of cDDP (μM) and percentage of cell viability was calculated
ed colorimetric MTT assay after 72 h of treatment. White columns repre-
and dark-gray columns (under 0 μg ml–1 BV ) represent viability obtained
, 40 or 50 μg ml–1 BV) represent cell viability obtained by combined treat-
sponding cDDP treatment (P < 0.05).
cells. New therapeutic approaches have attempted to use chemo-
therapeutic agents derived from venoms of animals and the most
frequently used in recent years is venom derived from A. mellifera
(Gajski et al., 2012; Gajski and Garaj-Vrhovac, 2013; Oršolić, 2012;
Son et al., 2007).
BV is a complex mixture of different active compounds and its
toxic effects could be largely attributed to its small protein MEL
that comprises around 19% of dry BV in our sample. PLA2 whose
activity is enhanced by MEL, as well as other peptide compo-
nents such as apamin, MCD peptide and/or tertiapin, was identi-
ﬁed in the present study as well. Those are the components with
known cytotoxic effects towards a variety of cells and are likely
to be responsible for the effects encountered in our study.
It has also been demonstrated that BV inhibits the growth of
several types of cancer cell lines (Hu et al., 2006; Ip et al.,
2008a, b, 2012; Jang et al., 2003; Jo et al., 2012; Lee et al., 2007;
Moon et al., 2006; Park et al., 2011). Previously, we reported that
BV is cytotoxic against different types of tumour and non-
tumour cell lines in vitro (Gajski et al., 2011). Those results
showed a decreased viability after BV treatment that was more
prominent in tumour than in non-tumour cells suggesting that
BV preferentially kills tumour cells. In addition to evaluating
the cytotoxic effect of BV alone, and the morphological changes
and the type of cell death induced after BV treatment, the pres-
ent study aimed to investigate the possible combined antican-
cer ability of BV and cisplatin towards tumour cells in vitro in a
narrower concentration range around IC50 values. This was done
using two different cultured human cell lines: human cervical
carcinoma HeLa and laryngeal carcinoma HEp-2 cells and their
cisplatin-resistant sublines HeLa CK and CK2 cells, respectively.
As the properties of carcinogenic agents are growth-inhibition
power and the ability to induce cell death, these properties are
widely used in anticancer therapies. In the present study, we
examined the cytotoxic effect of the whole BV and its impact
on cisplatin cytotoxicity on two tumour cells lines and their sub-
lines resistant to cisplatin. Using the spectrophotometric MTT
assay, we ﬁrst determined cell viability after treatment, whereas
using light and ﬂuorescent microscopy, in addition to Western
blot analysis, we described morphological changes and the type
of cell death induced. Our results showed that BV was cytotoxic
to all tested cell types and that cytotoxicity was dose- and cell-
type dependent. Parental HeLa and HEp-2 cells exhibited almost
the same sensitivity towards BV treatment. In contrast, in their
drug-resistant sublines we observed a different pattern of sensi-
tivity. HeLa CK cells were more sensitive towards BV than the
parental cells, whereas CK2 cells displayed resistance towards
BV. Such differences may be as a result of the biological and
genetic variations among the investigated cell types.
The cytotoxic effect of BV could be based on the effect of MEL.
Speciﬁcally, this compound shares its amphipatic properties
with a series of peptides that are characterized by their capacity
to disturb cell membrane bilayer integrity, either by creation of
defects, disruption, or through pore formation. The resulting
opening in the lipid bilayer leads to the collapse of transmem-
brane electrochemical gradients (Bechinger and Lohner, 2006).
In contrast to the normal cells with low membrane potential,
the cell membranes of tumour cells maintain a large membrane
potential. Therefore, many lytic peptides together with MEL
selectively disrupt the tumour cell membranes rather than those
of normal cells, and that could be the important mechanism of
the anticancer activity of BV (Holle et al., 2003; Moon et al.,
2006; Son et al., 2007).The collapse of the membrane integrity was conﬁrmed in our
system by the staining of treated cells with EtBr, a dye that only
enters the cells with a damaged cell membrane. In all cell lines
tested we observed similar morphological alterations induced
by BV. These changes occurred rapidly after cell treatment. Cell
rounding and granulation, as well as detachment from the
substratum, along with the staining with ﬂuorescent dye EtBr
suggests the cell membrane damage as the cause of cell death,
and the necrosis as the most probable type of the cell death in
the given concentrations. In the literature there are contradic-
tory data about the type of cell death which could be induced
by BV. BV caused apoptosis in lung carcinoma cells, hepatoma
cells, leukemic cells, breast cancer cells, cervical epidermoid car-
cinoma cells, synovial ﬁbroblasts, prostate cancer cells, bladder
cancer cells and melanoma cells (Hong et al., 2005; Hu et al.,
2006; Ip et al., 2008a, b, 2012; Jang et al., 2003; Moon et al.,
2006; Park et al., 2011; Tu et al., 2008). Recently reported
results demonstrate that in ﬁbroblast-like synoviocytes, in addi-
tion to apoptotic-like cell death induced by BV, necrotic cell
death was present as well whereas in human mammary carci-
noma cells, cervical carcinoma cells and Chinese hamster lung
ﬁbroblasts both apoptotic and necrotic activities were encoun-
tered (Oršolić, 2009; Oršolić et al., 2003; Stuhlmeier, 2007). In
addition, Lee et al. (2007) in their study on human lymphoma
cells did not observe sub-G1 fractions or cleavage of caspase-9,
-3 or PARP suggesting that BV induced cell death but these
cellular events were not accompanied by the activation of the
apoptotic machinery.
In the present study, the effects of BV were related to necrosis,
which was conﬁrmed by ﬂuorescent microscopy and Western
blot analysis. Although decades of research clariﬁed the path-
ways that regulate apoptosis and allowed the development of
novel diagnostic and therapeutic modalities in cancer treatment,
only recently has the signiﬁcance of necrosis become the focus
of investigations (Amaravadi and Thompson, 2007). Necrosis is
an irreversible inﬂammatory form of cell death with a possible
implication for cancer therapy. Necrotic cell death is often
referred to as unscheduled cell death, suggesting that within a
multicellular organism it is an unregulated process. The disrup-
tion of the plasma membrane that is characteristic of necrotic
cell death leads to the spillage of intracellular proteins that
activates a damage response from the host immune system
(Amaravadi and Thompson, 2007; Zeh and Lotze, 2005). This
rapid inﬂammatory response and immune ampliﬁcation of the
damage signal is in contrast to apoptotic cells that are silently
removed by tissue macrophages. Thus, necrosis was viewed as
strictly a pathologic form of cell death that is not a physiologi-
cally programmed process. However, a large number of experi-
mental data indicate that, much like apoptosis, speciﬁc genes
have evolved to regulate necrotic cell death, suggesting that
necrosis may be a well-regulated process activated by rather
speciﬁc physiological and pathological stimuli (Amaravadi and
Thompson, 2007; Festjens et al., 2006; Golstein and Kroemer,
2007; Proskuryakov and Gabai, 2010). Hence, necrosis is not to
be excluded as a possible way of cancer cell death.
Most of the anticancer agents, including cisplatin, can induce
drug resistance. In order to interact with intracellular targets,
they need to penetrate through membranes. Once they have
reached the cytosol many of them are deactivated and than
transported out of the cell before interacting with intracellular
targets (Köberle et al., 2010; Pérez-Tomás, 2006; Schweizer,
2009; Stewart, 2007). In order to battle such resistance and to
reduce normal cell cytotoxicity, the development of novel drugs
and delivery systems with novel mode of actions and high
cancer cell selectivity are crucial. In the search for new cancer
agents and delivery systems, cationic amphiphilic peptides such
as MEL have recently attracted attention owing to their novel
mode of actions and decreased possibility of resistance develop-
ment (Hoskin and Ramamoorthy, 2008; Leuschner and Hansel,
2004; Papo and Shai, 2005; Schweizer, 2009).
In our study, pre-treatment with BV enhanced cytotoxicity of
cisplatin in all cell lines. We used the isobologram analysis
method to determine the extent of synergism when combining
BV and cisplatin. The synergy index (q) on HeLa and HeLa CK cell
lines, for all the concentrations tested, indicated that a combina-
tion of BV and cisplatin could be synergistic although the syner-
gistic effect was not signiﬁcant. As for the HEp-2 and CK2 cells,
the same was observed only for certain BV and cisplatin concen-
trations, whereas other BV and cisplatin concentrations gave
only an additive effect. Nevertheless, not only is there a direct
effect of BV on the growth of tested tumour cells, but combined
BV and cisplatin treatment showed enhanced cytotoxicity which
could be useful from the point of minimizing the cisplatin
concentration during chemotherapy. The possible mechanism
of action could be a creation of defects, disruption and pore
formation in the cell membrane bilayer by MEL, enhancing
cisplatin uptake and accumulation and thus causing synergistic
i.e. enhanced cytotoxic effect of cisplatin. The effects of BV and
MEL on cytotoxicity of different cytostatic drugs was previously
noticed in leukemic L1210 cells (Lazo et al., 1985), HeLa cells,
Chinese hamster lung ﬁbroblasts V79 cells (Oršolić, 2009) and
human ovarian cancer A2780cp cells (Alizadehnohi et al.,
2012). Oršolić (2009) investigated the cytotoxic effects of BV
applied alone or in combination with the DNA damaging
drug bleomycin on HeLa and V79 cells. Bleomycin caused a
dose-dependent decrease in cell survival, and when used with
a non-lethal dose of BV, its lethal effect was potentiated. Oršolić
(2009) concluded that BV, by preventing the repair of damaged
DNA, increases bleomycin lethality and inhibits recovery from
the bleomycin-induced damage. Moreover, Alizadehnohi et al.
(2012) showed that lethal effects of cisplatin are potentiated
by the addition of a non-lethal dose of BV. As DNA is the main
target of cisplatin, it is very likely that BV is able to potentiate
the lethal effect of cisplatin in this way. Although the detailed
mechanism for the action of BV and cisplatin needs further
clariﬁcation, the inhibitory effect on tumour cell lines is appar-
ent. Because cisplatin cytotoxicity was enhanced with another
drug, in this particulate case with BV, combination therapy
may help overcome the challenge of tumour resistance towards
standard chemotherapy.
In conclusion, BV is a mixture of different active compounds
and its toxic effects could be largely attributed to its small
protein MEL that comprises around 19% of dry venom in our
sample, PLA2 which activity is enhanced by MEL, in addition to
other peptide components such as apamin, MCD peptide and/
or tertiapin that were identiﬁed in the course of our study. BV,
given in the range of 30 to 60 μg ml–1, was cytotoxic to parental
cervical HeLa and laryngeal HEp-2 carcinoma cells. Their cisplatin-
resistant sublines exhibited an opposite pattern of sensitivity: HeLa
CK cells were more sensitive to BV than their parental HeLa cells,
whereas CK2 cells were resistant compared with HEp-2 cells. BV
given alone induced very fast necrosis. The combined treatment
of BV and cisplatin induced an additive and/or weak synergistic
effect towards all the tested cell lines, suggesting that BV couldenhance the killing effect of selected cells when combined with
cisplatin, therefore, a greater anticancer effect could be triggered
if BV was used in the course of chemotherapy. Minimizing the
cisplatin concentration during chemotherapy by the addition of
compounds that increase their cytotoxicity could be very useful
for the patients, and also from the point of reducing and/or post-
poning the development of cisplatin resistance. Activities displayed
by BV alone and by its combination with cisplatin could merit
clinical investigation as a new agent in the treatment of cancer.
In view of accumulating evidence on anti-proliferative and pro-cell
death activity, BV could be used in the development of antitumor
drugs. Nevertheless, more studies are required to show the suit-
ability and safety of these types of drugs in anticancer therapies.
Acknowledgement
This work was supported by funds of the Ministry of Science,
Education and Sport of the Republic of Croatia (grant nos.
022-0222148-2125, 098-0982913-2748 and 098-0982915-2945).Conflict of Interest
The Authors did not report any conﬂict of interest.
References
Alizadehnohi M, Nabiuni M, Nazari Z, Safaeinejad Z, Irian S. 2012. The
synergistic cytotoxic effect of cisplatin and honey bee venom on
human ovarian cancer cell line A2780cp. J. Venom Res. 3: 22–27.
Amaravadi RK, Thompson CB. 2007. The roles of therapy-induced
autophagy and necrosis in cancer treatment. Clin. Cancer Res.
13: 7271–7279. DOI: 10.1158/1078-0432.CCR-07-1595.
Ashagbley A, Samadder P, Bittman R, Erukulla RK, Byun HS, Arthur G.
1996. Synthesis of ether-linked analogues of lysophosphatidate and
their effect on the proliferation of human epithelial cancer cells
in vitro. Anticancer Res 16: 1813–1818.
Baek YH, Huh JE, Lee JD, Choi do Y, Park DS. 2006. Antinociceptive effect
and the mechanism of bee venom acupuncture (Apipuncture) on
inﬂammatory pain in the rat model of collagen-induced arthritis:
Mediation by alpha2-Adrenoceptors. Brain Res. 1073-1074: 305–310.
DOI: 10.1016/j.brainres.2005.12.086.
Bechinger B, Lohner K. 2006. Detergent-like actions of linear amphipathic cat-
ionic antimicrobial peptides. Biochim. Biophys. Acta 1758: 1529–1539.
DOI: 10.1016/j.bbamem.2006.07.001.
Boulikas T, Vougiouka M. 2003. Cisplatin and platinum drugs at the
molecular level. (Review). Oncol. Rep. 10: 1663–1682.
Bradford MM. 1976. A rapid and sensitive method for the quantitation of
microgram quantities of protein of protein utilizing the principle of
protein-dye binding. Anal. Biochem. 72: 248–254.
Brozović A, Majhen D, Roje V, Mikac N, Jakopec S, Fritz G, Osmak M,
Ambriović Ristov A. 2008. αVβ3 integrin mediated drug resistance in
human laryngeal carcinoma cells is caused by glutathione dependent
elimination of drug induced reactive oxidative species.Mol. Pharmacol.
74: 1–9. DOI: 10.1124/mol.107.043836.
Brozović A, Ambriović-Ristov A, Osmak M. 2010. The relationship
between cisplatin-induced reactive oxygen species, glutathione,
and BCL-2 and resistance to cisplatin. Crit. Rev. Toxicol. 40: 347–359.
DOI: 10.3109/10408441003601836.
Cherniack EP. 2010. Bugs as drugs, Part 1: Insects: the "new" alternative
medicine for the 21st century? Altern. Med. Rev. 15: 124–135.
Cragg GM, Newman DJ. 2000. Antineoplastic agents from natural
sources: achievements and future directions. Expert Opin. Investig.
Drugs 9: 2783–2797. DOI: 10.1517/13543784.9.12.2783.
da Rocha AB, Lopes RM, Schwartsmann G. 2001. Natural products in
anticancer therapy. Curr. Opin. Pharmacol. 1: 364–369. DOI: 10.1016/
S1471-4892(01)00063-7.
Dempsey CE. 1990. The actions of melittin on membranes. Biochim.
Biophys. Acta 1031: 143–161. DOI: 10.1016/0304-4157(90)90006-X.
Eastman A. 1990. Activation of programmed cell death by anticancer
agents: cisplatin as a model system. Cancer Cells 2: 275–280.
Festjens N, Vanden Berghe T, Vandenabeele P. 2006. Necrosis, a well-
orchestrated form of cell demise: signalling cascades, important
mediators and concomitant immune response. Biochim. Biophys. Acta
1757: 1371–1387. DOI: 10.1016/j.bbabio.2006.06.014.
Fink D, Howell SB. 2000. How does cisplatin kill cells? In Platinum-based
Drugs in Cancer Therapy 7, Kelland LR, Farrell N (eds). Humana Press
Inc.: Totowa, New Jersey, 149–167.
Fuertes MA, Alonso C, Perez JM. 2003. Biochemical modulation of
cisplatin mechanisms of action: enhancement of antitumor activity
and circumvention of drug resistance. Chem. Rev. 103: 645–662.
DOI: 10.1021/cr020010d.
Gajski G, Garaj-Vrhovac V. 2009. Radioprotective effects of honeybee
venom (Apis mellifera) against 915-MHz microwave radiation-
induced DNA damage in Wistar rat lymphocytes: In vitro study. Int.
J. Toxicol. 28: 88–98. DOI: 10.1177/1091581809335051.
Gajski G, Garaj-Vrhovac V. 2011. Bee venom induced cytogenetic
damage and decreased cell viability in human white blood cells after
treatment in vitro: a multi-biomarker approach. Environ. Toxicol.
Pharmacol. 32: 201–211. DOI: 10.1016/j.etap.2011.05.004.
Gajski G, Čimbora-Zovko T, Osmak M, Garaj-Vrhovac V. 2011. Bee venom
and melittin are cytotoxic against different types of tumor and non-
tumor cell lines in vitro. Cancer Res. J. 4: 159–174.
Gajski G, Domijan AM, Garaj-Vrhovac V. 2012. Alterations of GSH and
MDA levels and their association with bee venom-induced DNA
damage in human peripheral blood leukocytes. Environ. Mol. Mutagen.
53: 469–477. DOI: 10.1002/em.21708.
Gajski G, Garaj-Vrhovac V. 2013. Melittin: a lytic peptide with anticancer
properties. Environ. Toxicol. Pharmacol. 36: 697–705. DOI: 10.1016/j.
etap.2013.06.009.
Garaj-Vrhovac V, Gajski G. 2009. Evaluation of the cytogenetic status of
human lymphocytes after exposure to a high concentration of bee
venom in vitro. Arh. Hig. Rada Toksikol. 60: 27–34. DOI: 10.2478/
10004-1254-60-2009-1896.
Golstein P, Kroemer G. 2007. Cell death by necrosis: towards a mole-
cular deﬁnition. Trends Biochem. Sci. 32: 37–43. DOI: 10.1016/j.
tibs.2006.11.001.
Gordaliza M. 2007. Natural products as leads to anticancer drugs. Clin.
Transl. Oncol. 9: 767–776. DOI: 10.1007/s12094-007-0138-9.
Habermann E. 1972. Bee and wasp venoms: The biochemistry and
pharmacology of heir peptides and enzymes are reviewed. Science
177: 314–322.
Heinen TE, da Veiga AB. 2011. Arthropod venoms and cancer. Toxicon
57: 497–511. DOI: 10.1016/j.toxicon.2011.01.002.
Hider RC. 1988. Honeybee venom: a rich source of pharmacologically active
peptides. Endeavour 12: 60–65. DOI: 10.1016/0160-9327(88)90082-8.
Holle L, Song W, Holle E, Wei Y, Wagner T, Yu X. 2003. A matrix
metalloproteinase 2 cleavable melittin/avidin conjugate speciﬁcally
targets tumor cells in vitro and in vivo. Int. J. Oncol. 22: 93–98.
Hong SJ, Rim GS, Yang HI, Yin CS, Koh HG, Jang MH, Kim CJ, Choe BK,
Chung JH. 2005. Bee venom induces apoptosis through caspase-3
activation in synovial ﬁbroblasts of patients with rheumatoid arthritis.
Toxicon 46: 39–45. DOI: 10.1016/j.toxicon.2005.03.015.
Hoskin DW, Ramamoorthy A. 2008. Studies on anticancer activities of
antimicrobial peptides. Biochim. Biophys. Acta 1778: 357–375. DOI:
10.1016/j.bbamem.2007.11.008.
Hu H, Chen D, Li Y, Zhang X. 2006. Effect of polypeptides in bee venom on
growth inhibition and apoptosis induction of the human hepatoma cell
line SMMC-7721 in-vitro and Balb/c nude mice in-vivo. J. Pharm.
Pharmacol. 58: 83–89. DOI: 10.1211/jpp.58.1.0010.
Ip SW, Liao SS, Lin SY, Lin JP, Yang JS, Lin ML, Chen GW, Lu HF, Lin MW,
Han SM, Chung JG. 2008a. The role of mitochondria in bee venom-
induced apoptosis in human breast cancer MCF7 cells. In Vivo
22: 237–245.
Ip SW, Wei HC, Lin JP, Kuo HM, Liu KC, Hsu SC, Yang JS, Mei-Dueyang,
Chiu TH, Han SM, Chung JG. 2008b. Bee venom induced cell cycle
arrest and apoptosis in human cervical epidermoid carcinoma Ca
Ski cells. Anticancer Res 28: 833–842.
Ip SW, Chu YL, Yu CS, Chen PY, Ho HC, Yang JS, Huang HY, Chueh FS, Lai TY,
Chung JG. 2012. Bee venom induces apoptosis through intracellular Ca
(2+) -modulated intrinsic death pathway in human bladder cancer cells.
Int. J. Urol. 19: 61–70. DOI: 10.1111/j.1442-2042.2011.02876.x.
Jang MH, Shin MC, Lim S, Han SM, Park HJ, Shin I. 2003. Bee venom
induces apoptosis and inhibits expression of cyclooxygenase-2
mRNA in human lung cancer cell line NCI-H1299. J. Pharmacol. Sci.
91: 95–104. DOI: 10.1254/jphs.91.95.Jin ZJ. 1980. Addition in drug combination. Acta Pharmacol. Sin. 1: 70–76.
Jo M, Park MH, Kollipara PS, An BJ, Song HS, Han SB, Kim JH, Song MJ,
Hong JT. 2012. Anti-cancer effect of bee venom toxin and melittin
in ovarian cancer cells through induction of death receptors and inhi-
bition of JAK2/STAT3 pathway. Toxicol. Appl. Pharmacol. 258: 72–81.
DOI: 10.1016/j.taap.2011.10.009.
Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. 1993.
Speciﬁc proteolytic cleavage of poly(ADP-ribose) polymerase:
an early marker of chemotherapy-induced apoptosis. Cancer Res.
53: 3976–3985.
Köberle B, Tomicic MT, Usanova S, Kaina B. 2010. Cisplatin resistance:
preclinical ﬁndings and clinical implications. Biochim. Biophys. Acta
1806: 172–182. DOI: 10.1016/j.bbcan.2010.07.004.
Kwon YB, Lee HJ, Han HJ, Mar WC, Kang SK, Yoon OB, Beitz AJ, Lee JH. 2002.
The water-soluble fraction of bee venom produces antinociceptive and
anti-inﬂammatory effects on rheumatoid arthritis in rats. Life Sci.
71: 191–204. DOI: 10.1016/S0024-3205(02)01617-X.
Lariviere WR, Melzack R. 1996. The bee venom test: a new tonic-pain test.
Pain 66: 271–277. DOI: 10.1016/0304-3959(96)03075-8.
Lazo JS, Hait WN, Kennedy KA, Braun ID, Meandzija B. 1985. Enhanced
bleomycin-induced DNA damage and cytotoxicity with calmodulin
antagonists. Mol. Pharmacol. 27: 387–393.
Lee YJ, Kang SJ, Kim BM, Kim YJ, Woo HD, Chung HW. 2007. Cytotoxicity
of honeybee (Apis mellifera) venom in normal human lymphocytes
and HL-60 cells. Chem. Biol. Interact. 169: 189–197. DOI: 10.1016/j.
cbi.2007.06.036.
Leuschner C, Hansel W. 2004. Membrane disrupting lytic peptides for
cancer treatments. Curr. Pharm. Des. 10: 2299–2310. DOI: 10.2174/
1381612043383971.
Liu X, Chen D, Xie L, Zhang R. 2002. Effect of honey bee venom on
proliferation of K1735M2 mouse melanoma cells in-vitro and growth of
murine B16 melanomas in-vivo. J. Pharm. Pharmacol. 54: 1083–1089.
DOI: 10.1211/002235702320266235.
Mehta RG, Pezzuto JM. 2002. Discovery of cancer preventive agents
from natural products: from plants to prevention. Curr. Oncol. Rep.
4: 478–486. DOI: 10.1007/s11912-002-0059-2.
Mickisch G, Fajta S, Keilhauer G, Schlick E, Tschada R, Alken P. 1990.
Chemosensitivity testing of primary human renal cell carcinoma by
a tetrazolium based microculture assay (MTT). Urol. Res. 18: 131–136.
DOI: 10.1007/BF00302474.
Moon DO, Park SY, Heo MS, Kim KC, Park C, Ko WS. 2006. Key regulators
in bee venom-induced apoptosis are Bcl-2 and caspase-3 in human
leukemic U937 cells through downregulation of ERK and Akt. Int.
Immunopharmacol. 6: 1796–1807. DOI: 10.1016/j.intimp.2006.07.027.
Nobili S, Lippi D, Witort E, Donnini M, Bausi L, Mini E, Capaccioli S. 2009.
Natural compounds for cancer treatment and prevention. Pharmacol.
Res. 59: 365–378. DOI: 10.1016/j.phrs.2009.01.017.
Osmak M. 1992. Collateral resistance or sensitivity of human larynx
carcinoma HEp2 cells resistant to cis-dichlorodiammineplatinum (II)
or vincristine sulfate. Neoplasma 39: 197–202.
Osmak M, Beketić-Orešković L, Matulić M, Sorić J. 1993. Resistance of
human larynx carcinoma cells to cisplatin, gamma-irradiation and meth-
otrexate does not involve overexpression of c-myc or c-Ki-ras oncogenes.
Mutat. Res. 303: 113–120. DOI: 10.1016/0165-7992(93)90023-O.
Osmak M, Eljuga D. 1993. The characterization of two human cervical
carcinoma HeLa sublines resistant to cisplatin. Res. Exp. Med. (Berl).
193: 389–396. DOI: 10.1007/BF02576247.
OršolićN, Šver L, Verstovšek S, Terzić S, Bašić I. 2003. Inhibition ofmammary
carcinoma cell proliferation in vitro and tumor growth in vivo by bee
venom. Toxicon 41: 861–870. DOI: 10.1016/S0041-0101(03)00045-X.
Oršolić N. 2009. Potentiation of bleomycin lethality in HeLa and V79 cells
by bee venom. Arh. Hig. Rada Toksikol. 60: 317–326. DOI: 10.2478/
10004-1254-60-2009-1936.
Oršolić N. 2012. Bee venom in cancer therapy. Cancer Metastasis Rev.
31: 173–194. DOI: 10.1007/s10555-011-9339-3.
Papo N, Shai Y. 2005. Host defense peptides as new weapons in
cancer treatment. Cell. Mol. Life Sci. 62: 785–790. DOI: 10.1007/
s00018-005-4560-2.
Park MH, Choi MS, Kwak DH, Oh KW, Yoon do Y, Han SB, Song HS, Song
MJ, Hong JT. 2011. Anti-cancer effect of bee venom in prostate
cancer cells through activation of caspase pathway via inactivation
of NF-κB. Prostate 71: 801–812. DOI: 10.1002/pros.21296.
Pérez-Tomás R. 2006. Multidrug resistance: retrospect and prospects in
anti-cancer drug treatment. Curr. Med. Chem. 13: 1859–1876. DOI:
10.2174/092986706777585077.
Proskuryakov SY, Gabai VL. 2010. Mechanisms of tumor cell necrosis.
Curr. Pharm. Des. 16: 56–68. DOI: 10.2174/138161210789941793.
Putz T, Ramoner R, Gander H, Rahm A, Bartsch G, Thurnher M. 2006.
Antitumor action and immune activation through cooperation of
bee venom secretory phospholipase A2 and phosphatidylinositol-
(3,4)-bisphosphate. Cancer Immunol. Immunother 55: 1374–1383.
DOI: 10.1007/s00262-006-0143-9.
Raghuraman H, Chattopadhyay A. 2007. Melittin: a membrane-active
peptide with diverse functions. Biosci. Rep. 27: 189–223. DOI: 10.1007/
s10540-006-9030-z.
Samadder P, Bittman R, Byun HS, Arthur G. 2004. Synthesis and use of
novel ether phospholipid enantiomers to probe the molecular basis
of the antitumor Effects of alkyllysophospholipids: correlation of
differential activation of c-Jun NH(2)-terminal protein kinase with
antiproliferative effects in neuronal tumor cells. J. Med. Chem.
47: 2710–2713. DOI: 10.1021/jm0302748.
Schweizer F. 2009. Cationic amphiphilic peptideswith cancer-selective toxicity.
Eur. J. Pharmacol. 625: 190–194. DOI: 10.1016/j.ejphar.2009.08.043.
Six DA, Dennis EA. 2000. The expanding superfamily of phospholipase A
(2) enzymes: classiﬁcation and characterization. Biochim. Biophys.
Acta 1488: 1–19. DOI: 10.1016/S1388-1981(00)00105-0.
Son DJ, Lee JW, Lee YH, Song HS, Lee CK, Hong JT. 2007. Therapeutic
application of anti-arthritis, pain-releasing, and anti-cancer effects
of bee venom and its constituent compounds. Pharmacol. Ther.
115: 246–270. DOI: 10.1016/j.pharmthera.2007.04.004.Stewart DJ. 2007. Mechanisms of resistance to cisplatin and
carboplatin. Crit. Rev. Oncol. Hematol. 63: 12–31. DOI: 10.1016/j.
critrevonc.2007.02.001.
Stuhlmeier KM. 2007. Apis mellifera venom and melittin block neither NF-
kappa B-p50-DNA interactions nor the activation of NF-kappa B, instead
they activate the transcription of proinﬂammatory genes and the
release of reactive oxygen intermediates. J. Immunol. 179: 655–664.
Tu WC, Wu CC, Hsieh HL, Chen CY, Hsu SL. 2008. Honeybee venom
induces calcium-dependent but caspase-independent apoptotic cell
death in human melanoma A2058 cells. Toxicon 52: 318–329. DOI:
10.1016/j.toxicon.2008.06.007.
Valentin E, Lambeau G. 2000. What can venom phospholipases A(2)
tell us about the functional diversity of mammalian secreted
phospholipases A(2)? Biochimie 82: 815–831. DOI: 10.1016/S0300-
9084(00)01168-8.
Varanda EA, Monti R, Tavares DC. 1999. Inhibitory effect of propolis and
bee venom on the mutagenicity of some direct- and indirect-acting
mutagens. Teratog. Carcinog. Mutagen. 19: 403–413. DOI: 10.1002/
(SICI)1520-6866(1999)19:6<403::AID-TCM4>3.0.CO;2-2.
Zeh HJ 3rd, Lotze MT. 2005. Addicted to death: invasive cancer and the
immune response to unscheduled cell death. J. Immunother. 28: 1–9.
Zisowsky J, Koegel S, Leyers S, Devarakonda K, Kassack MU, Osmak M,
Jaehde U. 2007. Relevance of drug uptake and efﬂux for cisplatin
sensitivity of tumor cells. Biochem. Pharmacol. 73: 298–307. DOI:
10.1016/j.bcp.2006.10.003.
